SCHEMBL17241

SCHEMBL17241

O=S(=O)(c1ccccc1)N1CCN(c2ccc(Br)cc2)CC1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.63
HPGD P15428 1/20 0.63
GCK P35557 1/20 0.60
LMNA P02545 4/20 0.59
MEN1 O00255 1/20 0.59
KMT2A Q03164 1/20 0.59
USP2 O75604 2/20 0.59
CYP1A2 P05177 2/20 0.59
CYP3A4 P08684 2/20 0.59
CYP2C9 P11712 2/20 0.59
CYP2C19 P33261 2/20 0.59
PKM P14618 1/20 0.58
GAA P10253 1/20 0.58
TSHR P16473 2/20 0.57
HSD17B10 Q99714 2/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
SMN1; SMN2 Q16637 2/20 0.56
POLB P06746 1/20 0.56
TDP1 Q9NUW8 1/20 0.55
MCOLN3 Q8TDD5 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2836518 0.94 ALDH1A1 (0.72) ALDH1A1HPGDLMNAMEN1KMT2A
SCHEMBL616835 0.88 ALDH1A1 (0.78) ALDH1A1HPGDGCKLMNAMEN1
SCHEMBL2839187 0.84 MEN1 (0.85) ALDH1A1LMNAMEN1KMT2APKM
SCHEMBL17403 0.84 GCK (0.64) ALDH1A1HPGDGCKLMNAMEN1
SCHEMBL7956164 0.81 LSS (0.70) ALDH1A1HPGDLMNAMEN1KMT2A
SCHEMBL10901539 0.81 GCK (0.61) ALDH1A1HPGDGCKLMNAMEN1
SCHEMBL28818511 0.81 HSD11B1 (0.60) ALDH1A1HPGDGCKLMNAMEN1
SCHEMBL2839583 0.81 GAA (0.60) ALDH1A1HPGDLMNAMEN1KMT2A
SCHEMBL31315858 0.80 ALDH1A1 (0.65) ALDH1A1LMNAUSP2PKMTSHR
SCHEMBL9344505 0.80 ALDH1A1 (0.65) ALDH1A1LMNAUSP2PKMTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609081-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES Amgen Inc. (US) 2013-07-03 EP disclosed
US-8431563-B2 Compounds that interact with glucokinase regulatory protein for the treatment of diabetes AMGEN INC. (US) 2013-04-30 US disclosed
US-8431563-B2 Compounds that interact with glucokinase regulatory protein for the treatment of diabetes AMGEN INC. (US) 2013-04-30 US disclosed
US-8431563-B2 Compounds that interact with glucokinase regulatory protein for the treatment of diabetes AMGEN INC. (US) 2013-04-30 US disclosed
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-09-06 US disclosed
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-09-06 US disclosed
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-09-06 US disclosed
WO-2012027261-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-03-01 WO disclosed
WO-2012027261-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES GCKR, GCK, SLC5A2 ALDH1A1 3293/4885HPGD 2367/4885GCK 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.